Evofem Biosciences, Inc. (EVFM) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Product sales, net	16.8	8.2	0.4
Product sales, net growth	104.2%	1748.4%
Operating Expenses:
Cost of goods sold	4.4	4.1	0.5
Research and development	25.0	33.1	17.1	22.2	43.4	23.5	6.6	34.4
Selling and marketing	44.0	113.2	56.5	10.2
General and administrative	27.6	24.7	30.1	20.3	34.2	12.1	5.5	7.6
Total operating expenses	101.0	175.0	104.1
Loss from operations	-84.1	-166.8	-103.6	-52.7	-77.6	-35.7	-12.0	-42.0
Operating margin	-499.6%	-2023.3%	-23234.1%

Other income (expense):
Interest income	0.1	0.0	0.2	0.5	0.1	0.1	0.1	0.0
Other expense, net	-2.1	-4.7	-2.1	0.3	-0.1	0.0
Loss on issuance of financial instruments	73.0		-64.0
Change in fair value of financial instruments	82.5	-33.7	27.3	-27.4
Total other income (expense), net	7.5	-38.4	-38.7	-27.3	-48.1	-69.6
Loss before income tax	-76.7	-205.2	-142.3	-80.0	-125.7	-105.3
Income tax expense	0.0	0.0	0.0	0.0	0.0	0.0
Net loss	-76.7	-205.2	-142.3	-80.0	-125.7	-105.3	-13.0	-43.2
Net loss attributable to common stockholders	-78.0	-206.2	-142.3		-125.8	-109.3

Net loss per share, basic	($1.34)	($23.63)	($2.12)	($1.99)	($5.74)	($55.78)	($5.66)	($18.91)
Net loss per share, diluted	($1.34)	($23.63)	($2.12)	($1.99)	($5.74)	($55.78)	($5.66)	($18.91)

Weighted-average shares used to compute net loss, basic	58.2	8.7	67.2	40.2	21.9	2.0	2.3	2.3
Weighted-average shares used to compute net loss, diluted	58.2	8.7	67.2